摘要
2019年底暴发的新型冠状病毒肺炎疫情在短时间内席卷全球,对人类健康造成了极大威胁。目前尚无针对该病毒的有效药物面市,对疫情的防控十分不利。SARS-CoV-2靶向药的研究一直是科研人员攻克的重难点,备受社会关注。SARS-CoV-2本身表达29个蛋白,同时与众多宿主蛋白相互作用,可筛选的药物靶点很多。目前已有几个靶点蛋白的结构被解析,并设计筛选了针对这些靶点的药物。例如靶向SARS-CoV-2 RNA聚合酶的核苷酸类似物瑞德西韦与索非布韦、靶向M pro的几种不可逆抑制剂以及靶向S蛋白的肽类化合物EK1。本文就借助结构生物学手段的SARS-CoV-2靶向药研发进展做出总结。
COVID-19,a global pandemic outbreak that has rapidly swept across the world,has posed an unprecedented threat to human health.No effective drug is against the SARS-CoV-2 virus is currently available on the market,thus placing the control and prevention of this pandemic at a significant disadvantage.Therefore,targeted drugs against SARS-CoV-2 have been a focus of many researchers.SARS-CoV-2,itself expressing 29 proteins,simultaneously interacts with various host proteins,thus leading to a large number of potential selectable drug targets.Among them,the structures of several protein targets have already been analyzed,and some drugs have been designed and selected on this basis.For example,the nucleotide analogs remdesivir and sofosbuvir that target SARS-CoV-2 RNA polymerase,several iIrreversible inhibitors that target Mpro,and the peptide compound EK1 that targets the spike protein.This article provides a summary of the R&D process,based on structural biology methods,of targeted drugs against SARS-CoV-2.
作者
刘雪晴
严汉池
LIU Xue-qing;YAN Han-chi(School of Life Sciences,Tianjin University,Tianjin 300110,China)
出处
《中国人兽共患病学报》
CAS
CSCD
北大核心
2021年第1期1-5,共5页
Chinese Journal of Zoonoses
基金
国家自然科学基金资助项目(No.31470731)。
作者简介
通讯作者:严汉池,Email:yanhanchi@sina.com,ORCID:0000-0001-6318-719X。
